[go: up one dir, main page]

MX2022001021A - Formulacion farmaceutica. - Google Patents

Formulacion farmaceutica.

Info

Publication number
MX2022001021A
MX2022001021A MX2022001021A MX2022001021A MX2022001021A MX 2022001021 A MX2022001021 A MX 2022001021A MX 2022001021 A MX2022001021 A MX 2022001021A MX 2022001021 A MX2022001021 A MX 2022001021A MX 2022001021 A MX2022001021 A MX 2022001021A
Authority
MX
Mexico
Prior art keywords
films
alginate
pharmaceutical formulation
present
monovalent cation
Prior art date
Application number
MX2022001021A
Other languages
English (en)
Inventor
Scott Boyer
Fredrik Hübinette
Original Assignee
Klaria Pharma Holding Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Klaria Pharma Holding Ab filed Critical Klaria Pharma Holding Ab
Publication of MX2022001021A publication Critical patent/MX2022001021A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se relaciona con películas que comprenden una sal de alginato de un catión monovalente o una mezcla de sales de alginato que contiene por lo menos una sal de alginato de un catión monovalente, y un compuesto de la fórmula (I), tal como cetamina, o una de sus sales farmacéuticamente aceptables. La presente invención se relaciona además con métodos para manufacturar tales películas y con el uso de tales películas en anestesia, manejo del dolor y tratamiento de enfermedades, en particular amnesia, depresión y trastorno bipolar.
MX2022001021A 2019-08-30 2020-08-27 Formulacion farmaceutica. MX2022001021A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1912505.3A GB201912505D0 (en) 2019-08-30 2019-08-30 Pharmaceutical formulation
PCT/EP2020/073940 WO2021037960A1 (en) 2019-08-30 2020-08-27 Pharmaceutical formulation

Publications (1)

Publication Number Publication Date
MX2022001021A true MX2022001021A (es) 2022-02-22

Family

ID=68207136

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022001021A MX2022001021A (es) 2019-08-30 2020-08-27 Formulacion farmaceutica.

Country Status (12)

Country Link
US (1) US20220280453A1 (es)
EP (1) EP4021405B1 (es)
JP (1) JP2022548349A (es)
KR (1) KR20220113920A (es)
CN (1) CN114901264A (es)
AU (1) AU2020338697A1 (es)
BR (1) BR112022001557A2 (es)
CA (1) CA3146475A1 (es)
GB (1) GB201912505D0 (es)
IL (1) IL290894A (es)
MX (1) MX2022001021A (es)
WO (1) WO2021037960A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102499414B1 (ko) 2016-11-15 2023-02-13 클라리아 파마 홀딩 에이비 약학적 제제
GB201709141D0 (en) 2017-06-08 2017-07-26 Klaria Pharma Holding Ab Pharmaceutical formulation
GB201808462D0 (en) 2018-05-23 2018-07-11 Klaria Pharma Holding Ab Pharmaceutical formulation
DE102021107829A1 (de) 2021-03-29 2022-09-29 Lts Lohmann Therapie-Systeme Ag. Oraler Dünnfilm
WO2024240033A1 (zh) * 2023-05-19 2024-11-28 宜昌人福药业有限责任公司 氯胺酮液体制剂及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201405958RA (en) * 2012-03-27 2014-10-30 Nicoccino Ab Nicotine formulation
FR2994844B1 (fr) * 2012-08-31 2015-01-02 Assist Publ Hopitaux De Paris Formulation gelifiante a base de ketamine
CA2987909C (en) * 2015-06-27 2022-04-26 Shenox Pharmaceuticals, Llc Ketamine transdermal delivery system
US10080763B2 (en) * 2015-08-17 2018-09-25 Sidmak Laboratories (India) Pvt. Ltd. Topical film delivery system
GB201709141D0 (en) * 2017-06-08 2017-07-26 Klaria Pharma Holding Ab Pharmaceutical formulation

Also Published As

Publication number Publication date
BR112022001557A2 (pt) 2022-03-22
KR20220113920A (ko) 2022-08-17
EP4021405A1 (en) 2022-07-06
WO2021037960A1 (en) 2021-03-04
AU2020338697A1 (en) 2022-03-17
JP2022548349A (ja) 2022-11-18
EP4021405B1 (en) 2024-11-06
US20220280453A1 (en) 2022-09-08
GB201912505D0 (en) 2019-10-16
CN114901264A (zh) 2022-08-12
IL290894A (en) 2022-04-01
CA3146475A1 (en) 2021-03-04

Similar Documents

Publication Publication Date Title
MX2022001021A (es) Formulacion farmaceutica.
NZ777871A (en) Small molecule modulators of il-17
PH12022550783A1 (en) Antiviral heterocyclic compounds
PH12018500147A1 (en) Benzodiazepine derivatives as rsv inhibitors
MX2023014378A (es) N-(hidroxialquil(hetero)aril)tetrahidrofurano carboxamidas como moduladores de canales de sodio.
MX2022015554A (es) Moduladores de molecula peque?a de interleucina 17 (il-17).
MY146606A (en) Oxadiazole substituted indazole derivatives for use as sphingosine 1-phosphate (s1p) agonists
MX2025001995A (es) Compuesto heterociclico, procedimiento para prepararlo y uso farmaceutico del mismo
MD20140037A2 (ro) Derivaţi de (4-fenilimidazol-2-il)etilamină utili ca modulatori ai canalului de sodiu
BR112013028095A2 (pt) inibidores de csf-1r para o tratamento de tumores cerebrais
PH12021552201A1 (en) Benzodiazepine derivatives as rsv inhibitors
MY199779A (en) Pyrrolopyrimidine compound and use thereof
MX2020012336A (es) Formulacion farmaceutica.
WO2018005794A3 (en) Novel non-systemic tgr5 agonists
WO2018005801A3 (en) Novel non-systemic tgr5 agonists
MX2021014161A (es) Metodos de tratamiento del sindrome de sjogren utilizando un inhibidor de la tirosina quinasa de bruton.
MX2020007985A (es) Inhibicion del canal ionico receptor de potencial transitorio a1.
MX2024014315A (es) Compuestos amido heteroaromaticos utiles en el tratamiento de enfermedades hepaticas
AU2018282104A1 (en) Use of vibegron to treat overactive bladder
MX2024011249A (es) Dosificacion no lineal de mirdametinib.
PH12019501560B1 (en) Insoluble complex or solvate thereof, pharmaceutical composition and use thereof
MX2023004516A (es) Uso de pridopidina y analogos para el tratamiento de la ansiedad y la depresion.
PH12022552553A1 (en) Substituted 3-phenoxyazetidin-1-yl-pyrazines having gpr52 agonistic activity
ZA202400679B (en) Dimethyl-substituted thiazololactam compound and use thereof
MX2020008413A (es) Composiciones para la prevencion o tratamiento de la uveitis.